Skip to main content

Advertisement

Table 4 Frequency of the most common adverse events during the multiple dose study

From: Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

System organ class Preferred term Multiple Dose Study
   Placebo Ferroquine
   (N = 7) 400 mg (N = 6) 600 mg (N = 6) 800 mg (N = 6) 1000 mg (N = 1)
Any class Any TEAE 6 (86) 6 (100) 6 (100) 6 (100) 1 (100)
Gastrointestinal disorders Any TEAE 4 (57) 3 (50) 4 (67) 5 (83) 1 (100)
  Abdominal pain 3 (43) 1 (17) 1 (17) 2 (33) 1 (100)
  Diarrhoea 0 0 0 2 (33) 0
  Nausea 1 (14) 2 (33) 2 (33) 3 (50) 0
  Toothache 1 (14) 1 (17) 0 2 (33) 0
  Vomiting 0 1 (17) 2 (33) 1 (17) 1 (100)
system disorders Any TEAE 1 (14) 1 (17) 3 (50) 1 (17) 0
  Dizziness 0 0 1 (17) 0 0
  Headache 1 (14) 1 (17) 2 (33) 1 (17) 0
  1. NOTE: N (%): count of patients (percentage per group); TEAE: treatment emergent adverse event